The World Health Organization projects that the share of the world’s population aged 60 years and older will almost double from 12% in 2015 to 22% by 2050. The Population Reference Bureau expects the number of Americans aged 65 and older to climb from 58 million in 2022 to 82 million by 2050.
The aging population is fueling demand for healthcare. US healthcare spending is forecast to hit $6 trillion in 2026 from $5.7 trillion in 2025. This trend reflects an expanding market for medical products companies.
Yet for large healthcare companies, legal issues can erode the benefits of favorable market conditions. That’s why Johnson & Johnson’s (NYSE:JNJ) proposed settlement of long-running talc lawsuits warrants significant investor attention.
Johnson & Johnson Looks to End a Decade of Talc Litigation
Johnson & Johnson (NYSE:JNJ) has agreed to pay $5.5 billion to settle lawsuits alleging that its talc-based products caused ovarian cancer. The proposed settlement covers nearly 80,000 outstanding claims.
For more than a decade, the company has made multiple attempts to resolve these lawsuits but suffered setbacks. Things recently tilted in the company’s favor after a federal judge questioned some key expert testimonies linking talc to individual cancer cases and disqualified one plaintiffs’ law firm.
If the settlement is finalized, it could reduce legal uncertainty that has weighed on Johnson’s shares and management attention for years.
How Johnson & Johnson Compares With AbbVie
Johnson & Johnson (NYSE:JNJ) and AbbVie (NYSE:ABBV) are two of the pharmaceutical industry leaders. But they present varying investment profiles.
Johnson runs a more diversified business that goes well beyond pharmaceutical products to include medical devices and surgical technology. AbbVie is heavily focused on branded medicines, particularly in areas like immunology and oncology therapy.
From a valuation standpoint, Johnson trades at a trailing price-to-earnings (P/E) multiple of about 30x, compared with roughly 70x for AbbVie. Johnson has a dividend yield of 2.05%. While J&J is a Dividend King with 64 consecutive years of raises, AbbVie pays a fatter 2.78%.
Hedge Funds Continue to Favor Johnson & Johnson
Some 113 hedge funds held Johnson & Johnson (NYSE:JNJ) shares at the end of Q1 2026, up from 104 in the previous quarter. Many prominent funds boosted their exposure to Johnson stock. Among them was Fisher Asset Management, which boosted its position by 5% to $2.26 billion. Adage Capital Management and Citadel Investment Group also increased their positions by 12% and 147%, respectively.
AbbVie (NYSE:ABBV)’s hedge fund holdings rose to 87 hedge funds in Q1, up from 84 in the previous quarter. That makes Johnson a more popular choice among elite investors.
Regarding short interests, both stocks have limited bearish bets. Johnson’s short interest was at 1.14% on July 15, representing 27.4 million shares with 3.7 days to cover. AbbVie’s short interest stood at 1.28%, representing 22.6 million shares with 3.5 days to cover.
Does Johnson & Johnson’s Proposed Talc Settlement Strengthen the Investment Case?
If the settlement is completed, it would allow investors to focus more on Johnson’s strong fundamentals rather than courtroom battles. It would also cut the noise around the stock and let investors pay more attention to Johnson’s long history of returning capital to shareholders.
However, there are more steps before Johnson can close the chapter on the talc issues. For instance, Johnson’s proposed settlement requires support of 95% of eligible claimants to become effective. Previous settlement plans have fallen through.
Nevertheless, Johnson offers exposure to a more diversified business compared to AbbVie. Moreover, Johnson enjoys stronger hedge fund interest, and the prospects of resolving the long-running talc legal dispute could improve investor sentiment around the stock.
While we acknowledge the risk and potential of JNJ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than JNJ and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: Should You Buy Lockheed Martin After Its Strong Q2 Earnings Rally? and AI-Fueled Demand Signals a Bigger Opportunity for Bloom Energy (BE) Investors.
Disclosure: None. Follow Insider Monkey on Google News.
Hedge Fund Resource Center